United Capital Financial Advisors LLC Takes Position in Pfizer Inc. $PFE

United Capital Financial Advisors LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 234,637 shares of the biopharmaceutical company's stock, valued at approximately $5,650,000.

Other large investors have also added to or reduced their stakes in the company. Godfrey Financial Associates Inc. bought a new position in shares of Pfizer in the fourth quarter valued at about $26,000. Keb Asset Management LLC bought a new stake in shares of Pfizer during the 2nd quarter worth about $26,000. HFM Investment Advisors LLC grew its stake in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 427 shares during the last quarter. Evolution Wealth Management Inc. raised its holdings in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 566 shares during the period. Finally, Abound Financial LLC bought a new position in Pfizer in the 4th quarter valued at about $31,000. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Shares of NYSE:PFE opened at $28.00 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer Inc. has a 52 week low of $23.58 and a 52 week high of $28.75. The firm has a market cap of $159.62 billion, a PE ratio of 36.85 and a beta of 0.34. The firm's fifty day moving average is $25.49 and its 200-day moving average is $26.29.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.Pfizer's quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer's payout ratio is currently 226.32%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COVID-19 vaccine. The updated Comirnaty formula is intended for adults 65 and older and younger individuals with qualifying health risks, with shipments beginning immediately. The approval supports Pfizer’s ability to compete in the upcoming respiratory-virus season and could provide seasonal revenue support. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
• Positive Sentiment: The FDA also approved updated COVID-19 vaccines from Moderna and Novavax-Sanofi, following guidance to target the dominant XFG variant. Pfizer’s immediate distribution and extensive real-world safety record may help preserve its position in the U.S. vaccine market, although demand remains difficult to forecast. US FDA approves updated COVID vaccines for 2026-27 season

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on PFE shares. Weiss Ratings cut Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a report on Monday, August 17th. UBS Group reiterated a "neutral" rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. Wolfe Research reissued an "underperform" rating and set a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. Bank of America lowered their price objective on Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Friday, July 10th. Finally, Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $28.28.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source